MCID: TRC008
MIFTS: 53

Trachoma

Categories: Eye diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Trachoma

MalaCards integrated aliases for Trachoma:

Name: Trachoma 12 73 20 54 44 15 70 32
Trachoma, Initial Stage 70
Trachoma, Active Stage 70
Active Stage Trachoma 12
Trachoma Dubium 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11265
ICD9CM 34 076 076.0 076.1
MeSH 44 D014141
UMLS 70 C0040592 C0153107 C0153108

Summaries for Trachoma

Disease Ontology : 12 A commensal bacterial infectious disease that results in infection located in eye, has material basis in Chlamydia trachomatis (A, B, Ba and C serovars), which is transmitted by contact with eye discharge from the infected person and transmitted by congenital method. The infection causes eyelid to turn inward which makes eyelashes to scratch the cornea.

MalaCards based summary : Trachoma, also known as trachoma, initial stage, is related to chlamydia and conjunctivitis. An important gene associated with Trachoma is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Permethrin and Trimethoprim have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and skin, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Wikipedia : 73 Trachoma is an infectious disease caused by bacterium Chlamydia trachomatis. The infection causes a... more...

Related Diseases for Trachoma

Diseases related to Trachoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 706)
# Related Disease Score Top Affiliating Genes
1 chlamydia 31.2 TNF MBL2 IL6 IL4 IL17A IL10
2 conjunctivitis 31.2 TNF IL6 IL4 IL10 HLA-B
3 bacterial conjunctivitis 30.7 TNF IL6 IL10
4 urethritis 30.5 TNF IL6 IL10
5 chronic conjunctivitis 30.3 TNF IL6 IL4 IL10
6 poliomyelitis 30.3 TNF IL4 IL10
7 plague 30.1 TNF IL6 IL10
8 covid-19 30.1 TNF IL6 IL4
9 diarrhea 30.1 TNF TGFB1 IL6 IL10
10 allergic disease 30.0 TNF IL6 IL4 IL10
11 cicatricial pemphigoid 30.0 IL4 HLA-DRB1 HLA-DQB1
12 dacryoadenitis 30.0 IL4 IL17A IL10
13 allergic conjunctivitis 30.0 TNF IL4 IL10
14 urinary schistosomiasis 30.0 IL4 IL10 HP
15 cervicitis 30.0 TNF IL6 IL10
16 typhoid fever 29.9 TNF IL6 HLA-DRB1 HLA-DQB1
17 filariasis 29.9 VEGFA TNF IL6 IL10
18 erythema multiforme 29.9 TNF IL6 IL4
19 schistosomiasis 29.9 TNF IL4 IL17A IL10
20 severe cutaneous adverse reaction 29.9 TNF HLA-DRB1 HLA-DQB1 HLA-B
21 background diabetic retinopathy 29.9 VEGFA TNF IL6
22 keratoconjunctivitis 29.9 TNF IL6 IL4 IL17A
23 pemphigoid 29.9 TNF IL4 HLA-DRB1 HLA-DQB1
24 endophthalmitis 29.8 VEGFA TNF IL6
25 dry eye syndrome 29.8 TNF IL6 EGF
26 chlamydia pneumonia 29.8 TNF IL6 IL4 IL10
27 leptospirosis 29.7 TNF IL6 IL4 IL10
28 keratitis, hereditary 29.6 VEGFA TNF IL6 IL17A IL10
29 q fever 29.6 TNF MBL2 IL6 IL4 IL10
30 microvascular complications of diabetes 1 29.5 VEGFA TNF IL6 CCN2
31 acute cystitis 29.5 TNF SERPINA3 IL6 IL10
32 proteasome-associated autoinflammatory syndrome 1 29.4 TNF IL6 IL4 IL17A IL10
33 conjunctival disease 29.3 TNF IL6 IL4 IL17A IL10
34 ocular cicatricial pemphigoid 29.3 TGFB1 IL4 HLA-DRB1 HLA-DQB1 CCN2
35 leprosy 3 29.3 TNF IL6 IL4 IL17A IL10 HLA-DRB1
36 rosacea 29.2 VEGFA TNF IL6 IL17A
37 bacterial infectious disease 29.1 TNF SERPINA3 MBL2 IL6 IL17A IL10
38 syphilis 29.1 TNF SERPINA3 IL6 IL17A HLA-DRB1
39 iritis 29.1 VEGFA TNF IL6 IL17A IL10 HLA-B
40 rhinitis 29.1 TNF IL6 IL4 IL17A IL10
41 cholera 29.1 TNF SERPINA3 IL6 IL4 IL10 EGF
42 eye disease 29.0 VEGFA TNF SERPINA3 IL6 IL4 IL17A
43 retinal detachment 29.0 VEGFA TNF TGFB1 IL6 IL10 CCN2
44 uveitis 28.9 TNF IL6 IL4 IL17A IL10 HLA-B
45 disease by infectious agent 28.9 TNF SERPINA3 MBL2 IL6 IL4 IL17A
46 reactive arthritis 28.7 TNF IL6 IL17A IL10 HP HLA-DRB1
47 parasitic helminthiasis infectious disease 28.7 TNF SERPINA3 IL6 IL4 IL17A IL10
48 dermatitis, atopic 28.7 TNF SERPINA3 IL6 IL4 IL17A IL10
49 skin disease 27.9 VEGFA TNF SERPINA3 IL6 IL4 IL17A
50 malaria 26.6 VEGFA TNF TGFB1 SERPINA3 MBL2 IL6

Graphical network of the top 20 diseases related to Trachoma:



Diseases related to Trachoma

Symptoms & Phenotypes for Trachoma

MGI Mouse Phenotypes related to Trachoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.22 CCN2 EGF ENG HLA-DQB1 IL10 IL17A
2 homeostasis/metabolism MP:0005376 10.22 CCN2 ENG HLA-DQB1 HP IL10 IL17A
3 hematopoietic system MP:0005397 10.17 ENG HLA-DQB1 HP IL10 IL17A IL4
4 endocrine/exocrine gland MP:0005379 10.16 CCN2 EGF HLA-DQB1 IL10 IL17A IL4
5 immune system MP:0005387 10.11 EGF HLA-DQB1 HP IL10 IL17A IL4
6 craniofacial MP:0005382 10.1 CCN2 ENG IL10 IL17A IL4 TGFB1
7 integument MP:0010771 10.06 CCN2 EGF ENG IL10 IL17A IL4
8 liver/biliary system MP:0005370 9.91 CCN2 HLA-DQB1 HP IL10 IL4 IL6
9 renal/urinary system MP:0005367 9.76 HLA-DQB1 HP IL17A IL4 IL6 MBL2
10 respiratory system MP:0005388 9.65 CCN2 ENG HLA-DQB1 IL10 IL17A IL4
11 skeleton MP:0005390 9.28 CCN2 IL10 IL17A IL4 IL6 MBL2

Drugs & Therapeutics for Trachoma

Drugs for Trachoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
2
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
3
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
4
Sulfamethoxazole Approved Phase 4 723-46-6 5329
5
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
6 Antimalarials Phase 4
7 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
8 Antibiotics, Antitubercular Phase 4
9
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
10 Ophthalmic Solutions Phase 3
11 Insect Repellents Phase 2
12 Vaccines Phase 1
13
Fluorometholone Approved, Investigational 426-13-1 9878
14 Pharmaceutical Solutions
15 Hormones
16 Lubricant Eye Drops
17 Hormone Antagonists
18 Anti-Allergic Agents
19 glucocorticoids
20 Anti-Inflammatory Agents
21 Immunoglobulin A

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Strategies for the Control of Blinding Trachoma: Effect of Fly Spray Completed NCT00347763 Phase 4
2 Cost-effectiveness of Three Alternative Azithromycin Treatment Strategies for Trachoma Control in Tanzania Completed NCT00347607 Phase 4
3 Determination of the Impact of Water and Health Education on Trachoma and Ocular C. Trachomatis in Niger Completed NCT00348478 Phase 4
4 Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso Completed NCT03187834 Phase 4 Azithromycin;Amoxicillin;Cotrimoxazole;Placebo
5 Research to Programs for Trachoma Elimination: Antibiotic Trial Completed NCT00792922 Phase 4 Azithromycin;Azithromycin
6 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Completed NCT00618449 Phase 4 Azithromcyin;Azithromycin
7 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4 mass treatment with oral azithromycin
8 Eliminating Trachoma With Repeat Mass Drug Treatment Completed NCT00322972 Phase 4 Mass treatment with oral azithromycin to an entire community
9 Trachoma Elimination With Repeated Mass Azithromycin Treatments Completed NCT00221364 Phase 4 Mass treatment with oral azithromycin to an entire village
10 A Randomised Controlled Trial of Non-absorbable (Silk) Sutures Verses Absorbable (Vicryl) Sutures During the Surgical Treatment of Trachomatous Trichiasis Completed NCT00522860 Phase 4
11 Azithromycine Pour la Vie Des Enfants au Niger - Implémentation et Recherche: Essai mortalité et résistance (Azithromycin for Child Survival in Niger: Mortality Trial and Resistance Trial) Recruiting NCT04224987 Phase 4 Azithromycin
12 Azithromycin for Child Survival in Niger: Delivery Trial Not yet recruiting NCT04774991 Phase 4 Azithromycin for Oral Suspension
13 Azithromycin Reduction to Reach Elimination of Trachoma Not yet recruiting NCT04185402 Phase 4 Azithromycin
14 Kebele Elimination of Trachoma for Ocular Health Not yet recruiting NCT03335072 Phase 4 Azithromycin
15 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
16 Trachoma Elimination Study by Focused Antibiotic (TESFA): The Impact of an Enhanced Antibiotic Treatment Regimen on Trachoma in Amhara, Ethiopia Suspended NCT03523156 Phase 4 Azithromycin mass treatment;Azithromycin targeted treatment
17 Azithromycin in Control of Trachoma II Withdrawn NCT00286026 Phase 4 Azithromycin
18 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
19 Clinical Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% (Instilled Twice Daily for 2 or 3 Days) Versus Oral Azithromycin in Treatment of Trachoma Completed NCT00356720 Phase 3 Azithromycin
20 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
21 Sanitation, Water, and Instruction in Face-washing for Trachoma I/II Recruiting NCT02754583 Phase 3 Azithromycin;Tetracycline
22 Nepal Elimination of Trachoma Study Withdrawn NCT02176057 Phase 2, Phase 3 Azithromycin
23 A Within-subject Laboratory and Field Trial to Test the Use of Commercially Available Insect Repellents Against Contact From Musca Sorbens, the Putative Vector of Trachoma Completed NCT03813069 Phase 2
24 A Phase I, Double-blind, Parallel, Randomised and Placebo-controlled Trial Investigating the Safety and Immunogenicity of a Chlamydia Vaccine, CTH522, in Healthy Adults Recruiting NCT03926728 Phase 1
25 Water Uptake for Health in Amhara Pilot Completed NCT02373657
26 Fluorometholone 0.1% as Perioperative Adjunct Therapy for Lid-rotation Surgery in Trachomatous Entropion and Trichiasis, Dose-varying Study Completed NCT01949454 Fluorometholone 0.1% ophthalmic solution
27 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial Completed NCT01767506
28 The Effect of Long-Term HEAD START Training on Surgical Skill Levels Completed NCT03135080
29 Partnership for the Rapid Elimination of Trachoma (PRET) Clinical Trial of Evaluation of Modified Instrumentation for Surgery to Correct Trichiasis Completed NCT00886015
30 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
31 REACH Côte d'Ivoire: Feasibility and Acceptability of Integrating Mass Distribution of Azithromycin to Children 1-11 Months Into a Trachoma Mass Drug Administration Campaign to Reduce Child Mortality Completed NCT04617626 Azithromycin
32 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis Completed NCT01178762 Azithromycin
33 Developing and Evaluating Trachoma Diagnosis Training Tools in Preparation for the Trachoma Elimination Endgame: Investigating the Effectiveness, Acceptability and Feasibility of an App-based Versus Slide-based IGA Test for Trachoma Graders Active, not recruiting NCT04002726
34 Developing and Evaluating Trachoma Diagnosis Training Tools in Preparation for the Trachoma Elimination Endgame: Development of a Smartphone Application to Capture Quality Images of Everted Eye Lids and Assessment of Its Acceptability and Feasibility Active, not recruiting NCT03997487
35 Évaluation de l'Utilisation d'un Photoscreener Comme méthode de dépistage Des problèmes Ophtalmologiques pédiatriques en Haïti Withdrawn NCT02655432

Search NIH Clinical Center for Trachoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Sulfacetamide
Sulfacetamide Sodium
Sulfisoxazole Diolamine

Cochrane evidence based reviews: trachoma

Genetic Tests for Trachoma

Anatomical Context for Trachoma

The Foundational Model of Anatomy Ontology organs/tissues related to Trachoma:

19
Eye

MalaCards organs/tissues related to Trachoma:

40
Eye, Bone, Skin, Breast, Kidney, Lung, T Cells

Publications for Trachoma

Articles related to Trachoma:

(show top 50) (show all 4075)
# Title Authors PMID Year
1
Airflow limitation, asthma, and Chlamydia pneumoniae-specific heat shock protein 60. 54 61
19119705 2008
2
Multiple Chlamydiaceae species in trachoma: implications for disease pathogenesis and control. 54 61
18177205 2008
3
Chlamydia pneumoniae as a respiratory pathogen. 61 54
11861211 2002
4
Immune response to chlamydial 60-kilodalton heat shock protein in tears from Nepali trachoma patients. 61 54
11447178 2001
5
Persistent Chlamydia trachomatis infections resist apoptotic stimuli. 54 61
11254605 2001
6
Characterization of B-cell responses to Chlamydia trachomatis antigens in humans with trachoma. 61 54
9393782 1997
7
Targeted antibiotics for trachoma: a cluster-randomized trial. 61
33674869 2021
8
Reducing suspicion of sexual abuse in paediatric chlamydial conjunctivitis using ompA genotyping. 61
33782064 2021
9
Use of modelling to modify trachoma elimination strategies affected by the COVID-19 pandemic. 61
33421962 2021
10
Implications of the COVID-19 pandemic in eliminating trachoma as a public health problem. 61
33449114 2021
11
Modelling trachoma post-2020: opportunities for mitigating the impact of COVID-19 and accelerating progress towards elimination. 61
33596317 2021
12
Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo. 61
33790370 2021
13
Complex emergencies and the control and elimination of neglected tropical diseases in Africa: developing a practical approach for implementing safe and effective mapping and intervention strategies. 61
33789715 2021
14
Application of leukocyte subsets and sperm DNA fragment rate in infertile men with asymptomatic infection of genital tract. 61
32921103 2021
15
WASH Upgrades for Health in Amhara (WUHA): study protocol for a cluster-randomised trial in Ethiopia. 61
33619183 2021
16
Community Hand-Dug Wells for Trachoma: A Cluster-Randomized Trial. 61
33534742 2021
17
Hopes for trachoma control in South Sudan. 61
33549180 2021
18
Contact lens management in a late-stage trachoma and concurrent severe dry-eye: A case report. 61
32327273 2021
19
Children as messengers of health knowledge? Impact of health promotion and water infrastructure in schools on facial cleanliness and trachoma in the community. 61
33524050 2021
20
Trachoma, Anti-Pgp3 Serology, and Ocular Chlamydia trachomatis Infection in Papua New Guinea. 61
31965155 2021
21
Significance of Crosslinking Approaches in the Development of Next Generation Hydrogels for Corneal Tissue Engineering. 61
33671011 2021
22
Population-Based Prevalence of Chlamydia trachomatis Infection and Antibodies in Four Districts with Varying Levels of Trachoma Endemicity in Amhara, Ethiopia. 61
33200728 2021
23
Lessons learned for surveillance strategies for trachoma elimination as a public health problem, from the evaluation of approaches utilised by Guinea worm and onchocerciasis programmes: A literature review. 61
33507903 2021
24
Twelve-Year Longitudinal Trends in Trachoma Prevalence among Children Aged 1-9 years in Amhara, Ethiopia, 2007-2019. 61
33534757 2021
25
Azithromycin Reduction to Reach Elimination of Trachoma (ARRET): study protocol for a cluster randomized trial of stopping mass azithromycin distribution for trachoma. 61
33407263 2021
26
Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases. 61
33452881 2021
27
Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019. 61
33500622 2021
28
Acceptability and perceived utility of different diagnostic tests and sample types for trachoma surveillance in the Bijagos Islands, Guinea Bissau. 61
33444436 2021
29
Chlamydia trachomatis intra-bacterial and total plasmid copy number in clinical urogenital samples. 61
33420252 2021
30
Host cell response and distinct gene expression profiles at different stages of Chlamydia trachomatis infection reveals stage-specific biomarkers of infection. 61
33397284 2021
31
Comparison of Smartphone Photography, Single-Lens Reflex Photography, and Field-Grading for Trachoma. 61
33021196 2020
32
Hijacking and Use of Host Kinases by Chlamydiae. 61
33321710 2020
33
The Importance of Failure: How Doing Impact Surveys That Fail Saves Trachoma Programs Money. 61
33025878 2020
34
In vivo confocal microscopy and trachomatous conjunctival scarring: Predictors for clinical progression. 61
32798249 2020
35
Effect of repeated epilation for minor trachomatous trichiasis on lash burden, phenotype and surgical management willingness: A cohort study. 61
33315876 2020
36
Tracing Ocular Conditions in 15,921 Interwar Refugees, Veria, Greece (1926-1940). 61
33781073 2020
37
COVID-19 and the Unfinished Agenda of VISION 2020. 61
33309690 2020
38
The upper eyelid levator weakening procedure for the correction of severe cicatricial entropion caused by trachoma. 61
33302671 2020
39
Facial cleanliness indicators by time of day: results of a cross-sectional trachoma prevalence survey in Senegal. 61
33203456 2020
40
Systematic review of the incidence of post-operative trichiasis in Africa. 61
33203380 2020
41
Mass administration of medicines in changing contexts: Acceptability, adaptability and community directed approaches in Kaduna and Ogun States, Nigeria. 61
33237933 2020
42
History through the eyes of a pandemic. 61
33009087 2020
43
Prevalence of refractive error and visual impairment among school-age children of Hargesia, Somaliland, Somalia. 61
33226104 2020
44
The simplified trachoma grading system, amended. 61
33177759 2020
45
Prophylaxis and treatment of diseases in western São Paulo state: the Sanitation Service and trachoma in the early twentieth century. 61
33338176 2020
46
Genomics of Ocular Chlamydia trachomatis after 5 years of SAFE interventions for trachoma in Amhara, Ethiopia. 61
33034349 2020
47
DjinniChip: evaluation of a novel molecular rapid diagnostic device for the detection of Chlamydia trachomatis in trachoma-endemic areas. 61
33109267 2020
48
The Chlamydia effector CT622/TaiP targets a nonautophagy related function of ATG16L1. 61
33055216 2020
49
Implications of the COVID-19 pandemic on eliminating trachoma as a public health problem. 61
33140063 2020
50
Single-Inclusion Kinetics of Chlamydia trachomatis Development. 61
33051378 2020

Variations for Trachoma

Expression for Trachoma

Search GEO for disease gene expression data for Trachoma.

Pathways for Trachoma

Pathways related to Trachoma according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 VEGFA TNF TGFB1 SERPINA3 MBL2 IL6
2
Show member pathways
13.83 VEGFA TNF TGFB1 IL6 IL4 IL17A
3
Show member pathways
13.56 VEGFA TNF TGFB1 IL6 IL4 IL17A
4
Show member pathways
13.43 TNF TGFB1 IL6 IL4 IL17A IL10
5
Show member pathways
13.32 TNF TGFB1 IL6 IL4 IL17A IL10
6
Show member pathways
13.28 VEGFA TNF TGFB1 IL6 IL4 IL17A
7
Show member pathways
13.2 TNF TGFB1 MBL2 IL6 IL10 EGF
8
Show member pathways
13.01 VEGFA TNF IL6 IL4 HLA-B EGF
9 12.84 VEGFA TGFB1 IL6 IL4 EGF
10
Show member pathways
12.82 TNF IL6 HLA-DRB1 HLA-DQB1 HLA-B
11 12.81 TNF IL6 HLA-DRB1 HLA-DQB1 HLA-B
12
Show member pathways
12.72 TNF TGFB1 IL6 EGF CCN2
13
Show member pathways
12.66 TNF IL4 IL10 HLA-DRB1 HLA-DQB1
14
Show member pathways
12.62 TNF TGFB1 IL6 IL4 IL17A IL10
15
Show member pathways
12.6 VEGFA TNF TGFB1 IL6 IL4 IL17A
16
Show member pathways
12.54 TNF TGFB1 IL6 IL4 IL17A IL10
17
Show member pathways
12.42 IL6 IL4 IL10 EGF
18
Show member pathways
12.38 TNF SERPINA3 IL6 IL4 HBB
19 12.38 TNF TGFB1 IL6 HLA-DRB1 HLA-DQB1 HLA-B
20
Show member pathways
12.35 TNF IL6 IL4 IL17A
21
Show member pathways
12.31 TNF TGFB1 IL4 IL10 HLA-DRB1 HLA-DQB1
22 12.26 TNF TGFB1 IL6 IL10 HLA-DRB1 HLA-DQB1
23 12.24 VEGFA TNF TGFB1 IL6 EGF
24 12.21 VEGFA TNF IL6 IL10
25 12.18 MBL2 HLA-DRB1 HLA-DQB1 HLA-B
26
Show member pathways
12.18 TNF TGFB1 IL6 IL4 IL17A IL10
27
Show member pathways
12.13 TGFB1 IL6 IL10 EGF
28 12.11 VEGFA TGFB1 IL6 EGF
29 12.06 TNF TGFB1 IL6 IL4
30 12.06 TNF IL6 IL4 IL10 ENG
31 11.98 TNF TGFB1 IL6 IL10
32 11.97 VEGFA TNF TGFB1 IL6
33 11.97 TNF IL6 IL4 HLA-DRB1 HLA-DQB1
34 11.95 MBL2 IL10 HLA-DRB1 HLA-DQB1
35 11.94 TGFB1 IL6 ENG EGF
36
Show member pathways
11.91 TGFB1 IL6 IL4 IL17A
37
Show member pathways
11.87 TGFB1 IL6 IL17A
38 11.86 VEGFA TNF TGFB1 IL6 IL4 IL17A
39 11.85 TNF IL4 IL17A IL10
40
Show member pathways
11.83 TNF TGFB1 IL6 IL17A IL10
41 11.81 TNF TGFB1 IL6 IL10
42 11.77 TNF IL6 IL10
43 11.71 TNF TGFB1 IL6 IL4 IL10
44 11.69 TNF TGFB1 ENG EGF
45
Show member pathways
11.68 VEGFA TNF IL6
46 11.61 TNF IL6 IL4 IL10
47 11.6 TNF TGFB1 IL6 IL4 EGF CCN2
48 11.59 VEGFA TGFB1 IL6
49 11.59 VEGFA TGFB1 IL6 EGF
50 11.59 TNF IL6 HP CCN2

GO Terms for Trachoma

Cellular components related to Trachoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 VEGFA TNF TGFB1 SERPINA3 MBL2 IL6
2 cell surface GO:0009986 9.7 VEGFA TNF TGFB1 MBL2 HLA-DRB1 HLA-B
3 blood microparticle GO:0072562 9.67 TGFB1 SERPINA3 HP HBB
4 ER to Golgi transport vesicle membrane GO:0012507 9.58 HLA-DRB1 HLA-DQB1 HLA-B
5 platelet alpha granule lumen GO:0031093 9.56 VEGFA TGFB1 SERPINA3 EGF
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.5 HLA-DRB1 HLA-DQB1 HLA-B
7 extracellular space GO:0005615 9.5 VEGFA TNF TGFB1 SERPINA3 MBL2 IL6
8 haptoglobin-hemoglobin complex GO:0031838 9.43 HP HBB

Biological processes related to Trachoma according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.16 MBL2 IL17A HP HLA-DRB1 HLA-DQB1 HLA-B
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 VEGFA TNF TGFB1 IL6 IL4 IL17A
3 inflammatory response GO:0006954 10.05 TNF TGFB1 SERPINA3 IL6 IL17A
4 positive regulation of cell proliferation GO:0008284 10.05 VEGFA TGFB1 IL6 IL4 EGF CCN2
5 positive regulation of transcription, DNA-templated GO:0045893 10.02 TNF TGFB1 IL6 IL4 IL10 HLA-DRB1
6 defense response to bacterium GO:0042742 10.01 TNF MBL2 IL10 HP
7 positive regulation of cell migration GO:0030335 10.01 VEGFA TGFB1 IL4 EGF
8 angiogenesis GO:0001525 10.01 VEGFA ENG EGF CCN2
9 negative regulation of gene expression GO:0010629 10 VEGFA TNF TGFB1 ENG CCN2
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.91 VEGFA TNF EGF
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 VEGFA TNF TGFB1 HLA-DRB1 CCN2
12 positive regulation of interleukin-6 production GO:0032755 9.9 TNF IL6 IL17A
13 response to organic substance GO:0010033 9.9 TNF TGFB1 IL10
14 platelet degranulation GO:0002576 9.89 VEGFA TGFB1 SERPINA3 EGF
15 interferon-gamma-mediated signaling pathway GO:0060333 9.88 HLA-DRB1 HLA-DQB1 HLA-B
16 positive regulation of MAPK cascade GO:0043410 9.88 VEGFA IL6 HLA-DRB1 EGF
17 positive regulation of endothelial cell proliferation GO:0001938 9.87 VEGFA IL10 EGF
18 response to glucocorticoid GO:0051384 9.87 TNF IL6 IL10
19 vasculogenesis GO:0001570 9.86 VEGFA TGFB1 ENG
20 positive regulation of interleukin-1 beta production GO:0032731 9.85 TNF IL6 IL17A
21 positive regulation of protein complex assembly GO:0031334 9.85 VEGFA TNF TGFB1
22 negative regulation of fat cell differentiation GO:0045599 9.85 TNF TGFB1 IL6
23 defense response to Gram-positive bacterium GO:0050830 9.85 TNF MBL2 IL6 IL17A
24 positive regulation of cell death GO:0010942 9.84 HP HBB CCN2
25 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 VEGFA TGFB1 IL6 EGF
26 antigen processing and presentation GO:0019882 9.83 HLA-DRB1 HLA-DQB1 HLA-B
27 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 VEGFA TNF TGFB1 IL6
28 positive regulation of protein kinase B signaling GO:0051897 9.83 VEGFA TNF TGFB1 ENG EGF
29 negative regulation of T cell proliferation GO:0042130 9.81 TGFB1 IL10 HLA-DRB1
30 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.81 TNF TGFB1 IL10
31 negative regulation of mitotic cell cycle GO:0045930 9.8 TNF TGFB1 IL10
32 liver regeneration GO:0097421 9.79 TGFB1 IL6 IL10
33 positive regulation of JAK-STAT cascade GO:0046427 9.78 TNF IL6 IL10
34 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 VEGFA TNF IL6 IL4
35 positive regulation of collagen biosynthetic process GO:0032967 9.74 TGFB1 ENG CCN2
36 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.73 TGFB1 IL6
37 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL6
38 surfactant homeostasis GO:0043129 9.73 VEGFA TGFB1
39 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.73 TNF IL6 IL17A
40 positive regulation of protein phosphorylation GO:0001934 9.73 VEGFA TNF TGFB1 HLA-DRB1 ENG CCN2
41 detection of bacterium GO:0016045 9.72 HLA-DRB1 HLA-B
42 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.72 TNF TGFB1
43 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 IL4 IL10
44 positive regulation of vascular permeability GO:0043117 9.71 VEGFA TGFB1
45 positive regulation of protein localization to early endosome GO:1902966 9.71 VEGFA EGF
46 positive regulation of MAP kinase activity GO:0043406 9.71 VEGFA TNF TGFB1 EGF
47 negative regulation of lipid storage GO:0010888 9.7 TNF IL6
48 endothelial cell apoptotic process GO:0072577 9.7 TNF IL10
49 cytokine-mediated signaling pathway GO:0019221 9.7 VEGFA TNF TGFB1 IL6 IL4 IL17A
50 vascular endothelial growth factor production GO:0010573 9.69 TNF IL6

Molecular functions related to Trachoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.3 VEGFA TNF TGFB1 SERPINA3 MBL2 IL6
2 cytokine activity GO:0005125 9.5 VEGFA TNF TGFB1 IL6 IL4 IL17A
3 type I transforming growth factor beta receptor binding GO:0034713 9.43 TGFB1 ENG
4 MHC class II receptor activity GO:0032395 9.4 HLA-DRB1 HLA-DQB1
5 peptide antigen binding GO:0042605 9.33 HLA-DRB1 HLA-DQB1 HLA-B
6 type II transforming growth factor beta receptor binding GO:0005114 9.32 TGFB1 ENG
7 hemoglobin binding GO:0030492 9.26 HP HBB
8 growth factor activity GO:0008083 9.17 VEGFA TGFB1 IL6 IL4 IL10 EGF

Sources for Trachoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....